Prophylactic and therapeutic efficacy of berberine on chronic toxoplasmosis in diabetic or hypertensive mice | ||||
| Parasitologists United Journal | ||||
| Article 8, Volume 17, Issue 2, August 2024, Page 126-134 PDF (1.48 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/puj.2024.304987.1257 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Wegdan Abd El Wahab  1; Mousa Ismail2; R abab Zalat3; Marwa Gh ieth4; Samah Abdel Gawa d5; Marwa Ahme d6; Amr M ousa7; Raghda Faro uk8; Mona Mona I Ali8
| ||||
| 1Departments of Medical Parasitology , Faculties of Medicine, Beni- Suef and Theodor Bilharz Research Institute , Beni-Suef , Egypt | ||||
| 2Faculties of Medicine,, Beni- Suef , Cairo ,Egypt | ||||
| 3Departments of Medical Parasitology, Theodor Bilharz Research Institute , Giza , Egypt | ||||
| 4Departments of Medical Parasitology, Faculties of Medicine,Beni- Suef ,Beni-Suef | ||||
| 5Departments of Medical Parasitology, Faculties of Medicine,Beni- Suef ,Beni-Suef, Egypt | ||||
| 6Departments of Pathology, Faculties of Medicine,Beni- Suef , Beni-Suef | ||||
| 7Departments of Pathology , Faculties of Medicine , King Salman International Universities, Tur Sinai | ||||
| 8Departments of Medical Parasitology, Faculties of Medicine , Beni- Suef ,Beni-Suef | ||||
| Abstract | ||||
| Background: Possible association between toxoplasmosis, and chronic diseases, e.g., hypertension (HTN) and diabetes mellitus (DM) are not uncommon. Therefore, searching for a new, safe, alternative and efficient natural product to treat toxoplasmosis in patients complaining of hypertension or diabetes is critically needed. Objective: To investigate the potential prophylactic and therapeutic efficacy of berberine on chronic toxoplasmosis in diabetic, and hypertensive mice compared to Spiramycin©. Material and Methods: A total number of 77 mice were divided into normal (n.=7), hypertensive (n.=35) and diabetic (n.=35) mice. Hypertension and type 1 diabetes were induced by 8% NaCl, and 2% Alloxan monohydrate, respectively. Both hypertensive, and diabetic mice were subdivided into five equal subgroups: control, berberine-prophylactic, Spiramycin©-treated, berberine-treated, and combined treatment (berberine and Spiramycin©). Berberine efficacy was assessed using parasitological and histopathological parameters. Results: Parasitological assessment showed that all treated subgroups showed a statistically significant reduction in the median tissue cysts count compared to infected control subgroups. Combined (berberine and Spiramycin©) showed the highest reduction rates of cysts count in both hypertensive and diabetic subgroups. For the prophylactic potential efficacy, berberine showed the least reduction rate in tissue cyst count in both hypertensive and diabetic subgroups. Histopathological assessment demonstrated moderate to marked improvement of brain, spleen and kidney inflammatory changes in all treated subgroups, the highest was recorded in the combined treated subgroups. Conclusion: Berberine is a promising adjuvant in treating toxoplasmosis associated with chronic diseases including diabetes mellitus and hypertension. | ||||
| Keywords | ||||
| berberine; diabetes; hypertension; Spiramycin©; toxoplasmosis | ||||
|
Statistics Article View: 39 PDF Download: 43 |
||||
